nVerses Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
nVerses Capital's NBIX Position: Q3 2026 in Review
nVerses Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,259 shares — an estimated $212K sold.
nVerses Capital first reported a position in NBIX in Q3 2024 and held it in 2 quarters. The position peaked at $392K in Q3 2024. 760 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- nVerses Capital reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
- nVerses Capital sold 1,259 Neurocrine Biosciences shares in Q3 2026, an estimated $212K.
- nVerses Capital first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 2 quarters.
- nVerses Capital's Neurocrine Biosciences position peaked at $392K in Q3 2024.
- 760 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on nVerses Capital's 13F filing for Q3 2026.